TSTickerStarGet alerts

APVO 10-Q filed 2026-11-16 | Key takeaways

APVO filed its 10-Q; the most relevant disclosure change is expanded Subsequent events: November 2026 warrant inducement: holders exercised 2,777,778 warrants at $1.08 per share for approximately $3.0M gross proceeds; company issued 13,888,890 new unregistered warrants at $1.08 per share, exercisable upon stockholder approval, expiring five years.

Share this story

Key takeaways

  • Cash declined to $8.3M as of September 30, 2026 from $21.6M at December 31, 2025, reflecting nine months of $19.1M net cash used in operations.

  • November 2026 warrant inducement: exercised 2,777,778 warrants at $1.08 for $3.0M gross proceeds; issued 13,888,890 new unregistered warrants at $1.08, exercisable upon stockholder approval, with five-year expiration from approval date.

  • August 2026 warrant inducement and private placement provided $4.5M gross proceeds; holders exercised 254,922 existing warrants at $4.03, and company issued 861,708 shares plus 5,583,150 new warrants at $4.03.

  • Niowave collaboration entered May 25, 2026 to develop radiopharmaceutical products; Niowave purchased 98,522 shares and 53,201 warrants for $500,000; collaboration scoped as 50/50 cost and revenue sharing under ASC 808.

  • CARE Fund grant awarded June 29, 2026 provides up to $1.5M reimbursement for APVO451 IND-enabling studies from June 2026 through June 2028; company recorded $0.03M receivable for nine months ended September 30, 2026.

  • Outstanding common warrants expanded to 6,058,397 shares as of September 30, 2026, with exercise prices ranging from $1.08 to $363,369.60; potential additional proceeds of $22.5M if all August 2026 warrants exercised.

  • Mipletamig RAINIER trial interim data: 79% CR/CRi rate (11 of 14 evaluable TP53-mutated AML patients) and 93% clinical benefit rate; 10 of 47 evaluable frontline patients proceeded to stem cell transplant.

Key metrics

Net loss - Q3Q3 2026
$6.5 million$1.0 million improvement from $7.5 million in Q3 2025
Net loss - Nine monthsNine months ended September 30, 2026
$19.6 million$0.6 million improvement from $20.2 million in prior year period
Net cash used in operating activities - Nine monthsNine months ended September 30, 2026
$19.1 million$1.3 million decrease from $20.4 million in prior year period
Cash and cash equivalentsSeptember 30, 2026
$8.3 million$13.3 million decrease from $21.6 million at December 31, 2025
Research and development expenses - Q3Q3 2026
$3.7 million$0.3 million decrease from $4.0 million in Q3 2025
General and administrative expenses - Q3Q3 2026
$2.9 million$0.7 million decrease from $3.6 million in Q3 2025

Disclosure changes

  • Subsequent events

    November 2026 warrant inducement: holders exercised 2,777,778 warrants at $1.08 per share for approximately $3.0M gross proceeds; company issued 13,888,890 new unregistered warrants at $1.08 per share, exercisable upon stockholder approval, expiring five years from approval date. October 2026 prospectus supplement filed under Rule 424(b)(5) reflecting $6.9M public float and $2.3M offering limit under General Instruction I.B.6. Rights Agreement extended to October 23, 2027 with purchase price changed to $14.56.

    Post-quarter warrant inducement provides $3.0M additional capital and expands warrant overhang by 13.9M shares; prospectus supplement limits ATM capacity to $2.3M
  • Collaborative arrangements

    Niowave Collaboration Agreement entered May 25, 2026 to develop radiopharmaceutical product candidates combining Aptevo's proprietary molecules with Niowave's radioisotopes; accounted for as 50/50 cost-sharing collaborative arrangement under ASC 808; no costs incurred for nine months ended September 30, 2026. Stock Purchase Agreement provided $500,000 gross proceeds for 98,522 shares and 53,201 warrants at $5.075 per share.

    New collaboration expands pipeline into radiopharmaceuticals; $500K investment from Niowave indicates strategic partnership; no near-term revenue impact as costs are shared equally
  • Government assistance

    CARE Fund grant award agreement signed June 29, 2026 provides up to $1.5M reimbursement for IND-enabling studies of APVO451 (trispecific antibody) from June 2026 through June 2028; recorded $0.03M receivable for nine months ended September 30, 2026; company early adopted ASU 2025-10 prospectively.

    Non-dilutive funding supports APVO451 development; $1.5M grant reduces cash burn for trispecific program over two-year period
  • Equity offerings and warrants

    August 12, 2026 warrant inducement and private placement: $4.5M gross proceeds from exercise of 254,922 existing warrants at $4.03 and private placement of 861,708 shares or pre-funded warrants plus 5,583,150 new warrants at $4.03; total warrant portfolio expanded to 6,058,397 shares outstanding as of September 30, 2026; potential $22.5M additional proceeds if all August 2026 warrants exercised.

    Warrant overhang expanded significantly; potential dilution from 6.1M warrants plus 5.6M shares issued; $22.5M potential future proceeds if exercised
  • Warrant inducement and deemed dividend

    Warrant inducement triggered $2.8M deemed dividend for Q3 2026, calculated as fair value of newly issued warrants plus incremental fair value over $1.0M exercise proceeds; affected net loss attributable to common stockholders calculation.

    Deemed dividend increases reported net loss attributable to common stockholders but does not impact net loss or total equity; affects per-share calculations
  • Operating segment disclosures

    Company operates as single segment (novel oncology therapeutics); CODM reviews cash, net loss, and operating expenses; no revenue generated in current period; clinical candidates include mipletamig (Phase 1b/2 in frontline AML) and ALG.APV-527 (Phase 1 in solid tumors).

    Single-segment reporting appropriate for clinical-stage company with no commercial products; all costs allocated to oncology pipeline

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow APVO in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert